UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Combined Anti-Aging Effect of Hydrolyzed Collagen Oligopeptides and Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells on Human Skin Fibroblasts

Molecules (Basel, Switzerland), 2024-04, Vol.29 (7), p.1468

2024

Volltextzugriff (PDF)

Risankizumab: Mechanism of action, clinical and translational science

Clinical and translational science, 2024-01, Vol.17 (1), p.e13706-n/a

2024

Volltextzugriff (PDF)

Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations

Journal of clinical pharmacology, 2015-04, Vol.55 (4), p.415-422

2015

Volltextzugriff (PDF)

Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure

Circulation Journal, 2015/05/25, Vol.79(6), pp.1237-1247

2015

Volltextzugriff (PDF)

Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice

Drug metabolism and disposition, 2012-02, Vol.40 (2), p.360-373

2012

Volltextzugriff (PDF)

Population Pharmacokinetic and Exposure–Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease

Clinical pharmacology and therapeutics, 2023-04, Vol.113 (4), p.839-850

2023

Volltextzugriff (PDF)

A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants

British journal of clinical pharmacology, 2024-01, Vol.90 (1), p.189-199

2024

Volltextzugriff (PDF)

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

The Lancet (British edition), 2022-05, Vol.399 (10340), p.2015-2030

2022

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients

Clinical pharmacokinetics, 2020-03, Vol.59 (3), p.311-326

2020

Volltextzugriff (PDF)

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

Clinical pharmacokinetics, 2019-06, Vol.58 (6), p.805-814

2019

Volltextzugriff (PDF)

Insulin self-association : Effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL)

Pharmaceutical research, 2007-09, Vol.24 (9), p.1636-1644

2007

Volltextzugriff (PDF)

Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis

Clinical pharmacology and therapeutics, 2024-09, Vol.116 (3), p.847-857

2024

Volltextzugriff (PDF)

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

Clinical pharmacokinetics, 2019-10, Vol.58 (10), p.1309-1321

2019

Volltextzugriff (PDF)

Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial

Arthritis & rheumatology (Hoboken, N.J.), 2023-06, Vol.75 (6), p.879-889

2023

Volltextzugriff (PDF)

The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition

European journal of pharmaceutical sciences, 2005-07, Vol.25 (4), p.369-378

2005

Volltextzugriff (PDF)

Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects

British journal of clinical pharmacology, 2018-11, Vol.84 (11), p.2572-2585

2018

Volltextzugriff (PDF)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

Journal of clinical pharmacology, 2019-12, Vol.59 (12), p.1656-1668

2019

Volltextzugriff (PDF)

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

Journal of the American Academy of Dermatology, 2023-12, Vol.89 (6), p.1149-1158

2023

Volltextzugriff (PDF)

Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease

Clinical therapeutics, 2024-01, Vol.46 (1), p.30-39

2024

Volltextzugriff (PDF)

Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes

The Journal of pharmacology and experimental therapeutics, 2019-06, Vol.369 (3), p.428-442

2019

Volltextzugriff (PDF)

Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection

Clinical therapeutics, 2021-03, Vol.43 (3), p.629-636

2021

Volltextzugriff (PDF)

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

Journal of Crohn's and colitis, 2021-12, Vol.15 (12), p.2001-2010

2021

Volltextzugriff (PDF)

Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study

Journal of clinical pharmacology, 2016-04, Vol.56 (4), p.474-483

2016

Volltextzugriff (PDF)

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease

Advances in therapy, 2023-05, Vol.40 (5), p.2311-2325

2023

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(58)

Publikationsform

Sprache

Englisch
(69)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(49)
Humans
(27)
Pharmacology & Pharmacy
(21)
Male
(15)
Pharmacokinetics
(15)
Female
(13)
Middle Aged
(11)
Monoclonal Antibodies
(11)
Psoriasis
(10)
Cytokines
(9)
Adult
(8)
Drug Dosages
(8)
Aged
(7)
Recombinant Proteins - Pharmacokinetics
(7)
Risankizumab
(7)
Treatment Outcome
(7)
Chemistry
(6)
Clinical Trials
(6)
Double-Blind Method
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The Combined Anti-Aging Effect of Hydrolyzed Collagen Oligopeptides and Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells on Human Skin Fibroblasts

Risankizumab: Mechanism of action, clinical and translational science

Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations

Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure

Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice

Population Pharmacokinetic and Exposure–Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease

A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

Insulin self-association : Effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL)

Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition

Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease

Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes

Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease

Suchergebnisse filtern